Surge in Value for Nasdaq-listed Chinese Herbal Firm
A Hong Kong-based biotech firm, although in its early stages and lacking revenue, has recently captured intense trading interest.
On Monday, the stock of Regencell, which specializes in traditional Chinese herbal remedies for childhood attention disorders such as ADHD and autism, more than tripled, witnessing an increase of over 280% by market close.
In 2025, Regencell's stock has skyrocketed by an astonishing 46,000% year-to-date. By the end of trading on Monday, the company, which was established in 2014 and began trading on Nasdaq under 'RGC' in 2021, reached a market cap close to $29.7 billion, as per S&P Capital IQ.
Regencell's CEO Yat-Gai Au holds sway over 86.24% of the company's shares, according to data from FactSet.
A Case of Speculation
Regencell isn't the first international stock to draw speculative attention. Such surprises in stock valuation have occurred before, notably with a Hong Kong-based fintech firm in August 2022.
Currently, Regencell's market value rivals other Nasdaq-traded companies, surpassing some well-known entities.
The company recently initiated a stock split in an effort to boost share liquidity and make them more attractive to investors. It's worth noting that stock splits don't alter the fundamental value of a business.
Focus on Alternative Remedies
Regencell's soaring stock coincides with a growing interest in alternative medicines, a trend that gained momentum when Robert F. Kennedy Jr. assumed the role of Secretary of the U.S. Department of Health and Human Services.
The stock is known for its volatility, demonstrated by significant daily swings like the 30% increase on March 21 followed by a similar drop the next day.
Unproven Treatments and Lack of Revenue
Despite dramatic increases in stock price, little conclusive evidence supports the efficacy or commercialization strategies for Regencell's ADHD and autism treatments.
Regencell's offerings are based on a proprietary Traditional Chinese Medicine (TCM) formula, developed in collaboration with TCM expert Sik-Kee Au.
Three liquid herbal concoctions, promoted to address various severities of conditions, have been crafted using natural components like detoxifying and circulation herbs.
The company aims to advance and eventually market these TCM products for ADHD and autism, as stated on its website.
However, Regencell has not yet recorded revenue nor sought regulatory approvals for its medicinal formulations. The 2023 and 2024 fiscal years saw net losses of $4.36 million and $6.06 million, respectively, according to an SEC filing.
The company's filing disclosed an absence of revenue-generating activities, regulatory licenses, patent filings, or distribution capabilities.
Regencell did not provide a comment upon CNBC’s request.
According to a November 2023 report, a trial involving 28 patients during a three-month period indicated symptom improvement in ADHD and autism treatment.
Previously, in 2021, Regencell tested a modified TCM formula on Covid-19 patients, leading to perceived improvements and prompting a September 2021 joint venture with Honor Epic Enterprises Limited for further research and commercialization efforts in Southeast Asia.
Market Speculation
Regencell's shares haven't seen extensive online discussion, though the dialogue swings between optimism and skepticism among retail traders.
One social media user compared its stock to a meme-based cryptocurrency, while another traders noted the potential for small scalping profits.
On LinkedIn, reactions varied from enthusiasm to caution over the lack of official news following May's price surge. Comments on various platforms highlight a mix of intrigue and unease regarding the company's volatile stock behavior.



Leave a Reply